Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Licenses Veridex's Gene-Methylation IP to Develop Prostate Cancer Dx

This article has been updated from a previous version, which incorrectly identified Myla LAi-Goldman as the CEO of LabCorp.
NEW YORK (GenomeWeb News) — LabCorp today said it has licensed a gene-methylation technology developed by Veridex in order develop a qPCR assay for prostate cancer.
LabCorp said it is the first company to license the technology, which is designed to detect the methylated GST-Pi gene. The reference lab said the test may "provide a more sensitive and accurate detection of prostate cancer" when used with histology, than would histology testing alone. 
According to LabCorp, the assay would be used in biopsies showing "suspicious histopathology," for patients who show elevated prostate-specific antigen values, and in patients whose biopsies are repeatedly negative.
The assay will "help clinicians resolve difficult-to-diagnose prostate cases and reduce the anxiety many patients experience when the status of their condition is uncertain," Myla Lai-Goldman, executive vice president, chief scientific officer, and medical director for LabCorp, said in a statement.
Financial terms of the agreement were not released.